(Morning News) Israel has approved the emergency use of Paxlovid, a crown oral drug produced by Pfizer.This is the first crown -resistant oral medication approved by Israel.
Xinhua News Agency reported that the Israeli Ministry of Health issued a statement on Sunday (December 26) saying that this oral medication will be used to treat patients with mild to median crown disease.The Israeli Ministry of Health has signed a drug purchase agreement with Pfizer, which is expected to arrive in Israel in the next few days.
Statement says that Paxlovid can inhibit the activity of protease necessary to copy the coronary virus in the human body.The statement also said that PaxLovid consists of two antiviral drugs. In Israel, it will be used for family treatment. The drugs will be used for three to five days after the symptoms of coronary patients, and the continuous medication time is five days.
Earlier, the US Food and Drug Administration (FDA) has approved the emergency use of Paxlovid on December 22 to treat adults and children aged 12 or above for the treatmentPeople with higher intensive risks.
The US FDA said that after evaluation of all available scientific basis, the drug may be effective in treating patients with mild diseases to the treatment of coronary disease.Common side effects may include damage to taste, diarrhea, hypertension, and muscle soreness.
According to the data of the Ministry of Health of the Israeli, as of December 26, the total number of Crown disease confirmed cases from Israel started from about 1.36 million, and a total of 8,242 deaths were accumulated.At present, about 6.5 million of the 9.3 million people in the country have been vaccinated at least one dose of coronary disease, about 5.88 million people have completed two doses of vaccination, and about 4.19 million people have been vaccinated.
